Robinson Blaine W, Felix Carolyn A
Division of Oncology, Children's Hospital of Philadelphia, PA, USA.
Methods Mol Biol. 2009;538:85-114. doi: 10.1007/978-1-59745-418-6_6.
Translocations and other rearrangements of the MLL gene at chromosome band 11q23 are biologically and clinically important molecular abnormalities in infant acute leukemias, leukemias associated with chemotherapeutic topoisomerase II poisons and, less often, acute leukemias in adults or myelodysplastic syndrome. Depending on the disease and the regimen, MLL-rearranged leukemias may be associated with inferior prognosis, and MLL rearrangements with some of the more than 60 known MLL-partner genes confer especially adverse effects as response to treatment (Blood 108:441-451, 2006). MLL rearrangements are usually evident as overt balanced chromosomal translocations by conventional cytogenetic analysis but up to one-third are cryptic rearrangements and occur in leukemias with del(11)(q23), a normal karyotype, or trisomy 11, the latter two of which sometimes are associated with partial tandem duplications of MLL itself (Proc Natl Acad Sci USA 97:2814-2819, 2000; Proc Natl Acad Sci USA 94:3899-3902, 1997). In addition, subsets of MLL rearrangements are complex at a cytogenetic level and/or molecular level, and fuse MLL with two different partner genes. Rapid and accurate methods to identify and characterize genomic breakpoint junctions and fusion transcripts resulting from the many types of MLL rearrangements are essential for risk group stratification, treatment protocol assignments, new partner gene discovery, understanding leukemia etiology and pathogenesis, and elucidating the impact of less common MLL-partner genes on biology and prognosis. Due to the vast heterogeneity in partner genes, typical gene-specific PCR based methods are not practical, especially when cytogenetics are normal or do not suggest involvement of a known partner gene of MLL. We have advanced seven different panhandle PCR based methods for cloning 5'-MLL-partner gene-3' and 5'-partner gene-MLL-3' genomic breakpoint junctions and identifying 5'-MLL-partner gene-3' fusion transcripts, all of which employ a stem-loop template shaped schematically like a pan with a handle and amplify the template without knowledge of the unknown partner sequence using primers all derived from MLL alone.
位于染色体11q23带的MLL基因易位及其他重排在婴儿急性白血病、与化疗拓扑异构酶II毒物相关的白血病以及较少见的成人急性白血病或骨髓增生异常综合征中是具有生物学和临床重要性的分子异常。根据疾病和治疗方案的不同,MLL重排的白血病可能预后较差,且MLL与60多种已知MLL伙伴基因中的一些发生重排会对治疗反应产生特别不利的影响(《血液》108:441 - 451, 2006)。通过传统细胞遗传学分析,MLL重排通常表现为明显的平衡染色体易位,但高达三分之一的是隐匿性重排,发生于伴有del(11)(q23)、核型正常或11三体的白血病中,后两者有时与MLL自身的部分串联重复有关(《美国国家科学院院刊》97:2814 - 2819, 2000;《美国国家科学院院刊》94:3899 - 3902, 1997)。此外,MLL重排的一些亚群在细胞遗传学水平和/或分子水平上较为复杂,且使MLL与两个不同的伙伴基因融合。快速准确地鉴定和表征由多种类型MLL重排产生的基因组断点连接和融合转录本,对于风险组分层、治疗方案分配、新伙伴基因发现、理解白血病病因和发病机制以及阐明较少见的MLL伙伴基因对生物学和预后的影响至关重要。由于伙伴基因存在巨大的异质性,典型的基于基因特异性PCR的方法并不实用,尤其是当细胞遗传学正常或未提示MLL的已知伙伴基因受累时。我们已经开发出七种不同的基于锅柄PCR的方法,用于克隆5'-MLL-伙伴基因-3'和5'-伙伴基因-MLL-3'基因组断点连接并鉴定5'-MLL-伙伴基因-3'融合转录本,所有这些方法都采用一种茎环模板,其示意图形状像一个带柄的锅,并且在不了解未知伙伴序列的情况下使用全部仅源自MLL的引物扩增模板。